Literature DB >> 6378975

Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.

S Eisenberg, D Gavish, Y Oschry, M Fainaru, R J Deckelbaum.   

Abstract

The effects of triglyceridemia on plasma lipoproteins were investigated in 16 hypertriglyceridemic (HTG) subjects (222-2,500 mg/dl) before and after the initiation of bezafibrate therapy. Bezafibrate caused a mean reduction of 56% in plasma triglyceride and increased the levels of lipoprotein and hepatic triglyceride lipases by 260 and 213%, respectively. The natures of very low density lipoprotein (VLDL), isolated at plasma density and of low and high density lipoprotein (LDL and HDL), separated by zonal ultracentrifugation, were determined. HTG-LDL appears as multiple fractions whereas HTG-HDL is seen predominantly as HDL3. HTG-VLDL is relatively poor in apoproteins and triglycerides but enriched in free and esterified cholesterol. HTG-LDL (main fraction) is depleted of free and esterified cholesterol but enriched in apoprotein and triglyceride. It is also denser and smaller than normal. HTG-HDL3 is denser than N-HDL3 and demonstrates compositional abnormalities similar to those of HTG-LDL. With the reduction of the VLDL mass, all abnormalities revert towards normal. This is accompanied by an increase in LDL-apoprotein B and cholesterol levels, which indicates an increased conversion of VLDL to LDL. Significant correlations between plasma triglyceride and the degree of all abnormalities are shown. The data obtained during treatment corroborate these relationships. The observations support the concept that most abnormalities reflect the degree of triglyceridemia. We suggest that plasma core-lipid transfer protein(s) is an effector of the abnormal cholesteryl ester distribution. Its prolonged action on increasingly large and slowly metabolized VLDL populations would entail a correspondingly excessive transfer of cholesteryl ester to VLDL and of triglyceride to LDL and HDL. It is calculated that, in moderate HTG, LDL and HDL contain only 50% of the normal cholesterol load. It is suggested that cholesteryl ester redistribution in HTG might be important in regulating metabolic events.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378975      PMCID: PMC370499          DOI: 10.1172/JCI111444

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Radioimmunoassay of human high density lipoprotein apo-protein A-1.

Authors:  M Fainaru; M C Glangeaud; S Eisenberg
Journal:  Biochim Biophys Acta       Date:  1975-04-29

2.  Separation of the main lipoprotein density classes from human plasma by rate-zonal ultracentrifugation.

Authors:  J R Patsch; S Sailer; G Kostner; F Sandhofer; A Holasek; H Braunsteiner
Journal:  J Lipid Res       Date:  1974-07       Impact factor: 5.922

3.  On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein.

Authors:  S Eisenberg; D W Bilheimer; R I Levy; F T Lindgren
Journal:  Biochim Biophys Acta       Date:  1973-12-20

4.  Very low density lipoprotein subfractions in a subject with broad-beta disease (Type 3 hyperlipoproteinemia) and a subject with endogenous lipemia (Type IV). Chemical composition and electrophoretic mobility.

Authors:  W R Hazzard; F T Lindgren; E L Bierman
Journal:  Biochim Biophys Acta       Date:  1970-05-05

5.  A comparison of heritable abnormal lipoprotein patterns as defined by two different techniques.

Authors:  D S Fredrickson; R I Levy; F T Lindgren
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

6.  Particle size and protein content of six fractions of the Sf 20 plasma lipoproteins isolated by density gradient centrifugation.

Authors:  W J Lossow; F T Lindgren; J C Murchio; G R Stevens; L C Jensen
Journal:  J Lipid Res       Date:  1969-01       Impact factor: 5.922

7.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

8.  Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans.

Authors:  T Sata; R J Havel; A L Jones
Journal:  J Lipid Res       Date:  1972-11       Impact factor: 5.922

9.  Metabolic relationships among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man.

Authors:  D E Wilson; R S Lees
Journal:  J Clin Invest       Date:  1972-05       Impact factor: 14.808

Review 10.  The plasma lecithins:cholesterol acyltransferase reaction.

Authors:  J A Glomset
Journal:  J Lipid Res       Date:  1968-03       Impact factor: 5.922

View more
  33 in total

1.  Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.

Authors:  L Kłosiewicz-Latoszek; W B Szostak
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

3.  Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach.

Authors:  L Berglund; J L Witztum; N F Galeano; A S Khouw; H N Ginsberg; R Ramakrishnan
Journal:  J Lipid Res       Date:  1998-04       Impact factor: 5.922

4.  Ethnic and gender susceptibility to metabolic risk.

Authors:  Scott M Grundy; Ian J Neeland; Aslan T Turer; Gloria Lena Vega
Journal:  Metab Syndr Relat Disord       Date:  2013-12-10       Impact factor: 1.894

5.  The effect of low density lipoprotein composition on the regulation of cellular cholesterol synthesis: a comparison in diabetic and non-diabetic subjects.

Authors:  D Owens; S McBrinn; P Collins; A Johnson; G H Tomkin
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

6.  Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.

Authors:  P Grützmacher; E H Scheuermann; W Siede; P D Lang; U Abshagen; H W Radtke; C A Baldamus; W Schoeppe
Journal:  Klin Wochenschr       Date:  1986-10-01

7.  Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.

Authors:  Toshihiro Sakurai; Akiko Sakurai; Boris L Vaisman; Marcelo J Amar; Chengyu Liu; Scott M Gordon; Steven K Drake; Milton Pryor; Maureen L Sampson; Ling Yang; Lita A Freeman; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

8.  Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.

Authors:  Sunil Suchindran; David Rivedal; John R Guyton; Tom Milledge; Xiaoyi Gao; Ashlee Benjamin; Jennifer Rowell; Geoffrey S Ginsburg; Jeanette J McCarthy
Journal:  PLoS Genet       Date:  2010-04-29       Impact factor: 5.917

9.  Presence of very low density lipoprotein compositional abnormalities in type 1 (insulin-dependent) diabetic patients; effects of blood glucose optimisation.

Authors:  A Rivellese; G Riccardi; G Romano; R Giacco; L Patti; G Marotta; G Annuzzi; M Mancini
Journal:  Diabetologia       Date:  1988-12       Impact factor: 10.122

10.  Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

Authors:  Eliete J B Bighetti; Patrícia R Patrício; Andrea C Casquero; Jairo A Berti; Helena C F Oliveira
Journal:  Lipids Health Dis       Date:  2009-11-23       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.